Effect of a Botanical Ingredient in Healthy Subjects With Anxiety and Poor Sleep Quality

NCT ID: NCT06154629

Last Updated: 2024-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-15

Study Completion Date

2024-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, controlled, double-blind, single-center clinical trial with two parallel arms depending on the product consumed (experimental product and placebo product) to analyze the efficacy of a botanical extract in reducing anxiety and improving sleep quality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product dose or placebo, depending on the group to which they have been assigned).

The product to be consumed is a botanical extract. Participants will consume the product for 90 days. They should consume one capsule one hour before going to sleep.

They will make a total of five visits to the research laboratory and the tests preestablished in the protocol will be performed. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain the results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Poor Quality Sleep

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Botanical ingredient

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Group Type EXPERIMENTAL

Botanical ingredient

Intervention Type DIETARY_SUPPLEMENT

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Control Group

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Group Type PLACEBO_COMPARATOR

Control group

Intervention Type DIETARY_SUPPLEMENT

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botanical ingredient

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Intervention Type DIETARY_SUPPLEMENT

Control group

Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults.
* Moderate levels of anxiety by STAI.
* Low sleep quality by PSQI.
* Volunteers able to understand the clinical study and willing to comply with its procedures and requirements.

Exclusion Criteria

* Serious or terminal illness.
* Subjects with body mass index above 32 kg/m2. Pregnant or lactating women.
* Participation in another study involving blood draws or dietary intervention.
* Organic dementias such as Alzheimer's, Huntington's disease, Parkinson's and senile dementia.
* Hypersensitivity to the components of the formula.
* Use of medications that alter cognitive functions or sleep, such as barbiturates, anticonvulsants, benzodiazepines, antidepressants, neuroleptics, alcohol and illicit drugs.
* Subjects with known allergy to some of the study components.
* Inability to understand the informed consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Católica San Antonio de Murcia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francisco Javier López Román

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catholic University of Murcia

Murcia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCAMCFE-00034

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.